New Age, Inc. NBEV
We take great care to ensure that the data presented and summarized in this overview for NewAge, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in NBEV
Top Purchases
Top Sells
About NBEV
NewAge, Inc. develops, markets, sells, and distributes healthy products in the United States, Japan, China, and internationally. The company operates in two segments, Direct / Social Selling and Direct Store. It provides health and wellness, energy drink, essential oil and anti-aging skincare, cosmetic, beverage, snacks, water and air filtration, and personal care products, as well as weight management, nutritional supplement, nutraceutical, and slenderiize products; diagnostic products, such as DNA testing and diagnostic kits and products; and CBD products. The company offers its products under the Tahitian Noni, LIMU, Zennoa, LIMU Blue Frog, Hiro Natural, TeMana, Lucim, Reviive, Puritii, and MaVie brands. It sells its products directly to customers, as well as through distributors, e-commerce sites, and direct-store-delivery systems. The company was formerly known as New Age Beverages Corporation and changed its name to NewAge, Inc. in July 2020. NewAge, Inc. was incorporated in 2010 and is headquartered in Denver, Colorado.
Insider Transactions at NBEV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 22
2021
|
Fred W Cooper Director |
BUY
Grant, award, or other acquisition
|
Indirect |
8,227,007
+40.47%
|
-
|
|
Nov 18
2021
|
Ed Brennan Director |
BUY
Open market or private purchase
|
Indirect |
500,000
+50.0%
|
$500,000
$1.22 P/Share
|
|
Nov 17
2021
|
Fred W Cooper Director |
BUY
Grant, award, or other acquisition
|
Indirect |
81,401
+2.06%
|
-
|
|
Sep 08
2021
|
Fred W Cooper Director |
BUY
Grant, award, or other acquisition
|
Indirect |
3,660,062
+49.12%
|
-
|
|
Jul 19
2021
|
Kevin Manion Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
213,904
+50.0%
|
-
|
|
Jul 02
2021
|
Gregory A Gould Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
73,110
-18.08%
|
$146,220
$2.24 P/Share
|
|
Mar 10
2021
|
Brent D Willis Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
175,000
+14.63%
|
-
|
|
Feb 02
2021
|
Fred W Cooper Director |
BUY
Grant, award, or other acquisition
|
Indirect |
131,340
+50.0%
|
-
|
|
Jan 29
2021
|
Gregory Fea Director |
BUY
Grant, award, or other acquisition
|
Direct |
31,153
+12.85%
|
-
|
|
Jan 29
2021
|
Timothy J Haas Director |
BUY
Grant, award, or other acquisition
|
Direct |
31,153
+5.21%
|
-
|
|
Jan 29
2021
|
Amy L. Kuzdowicz Director |
BUY
Grant, award, or other acquisition
|
Direct |
31,153
+22.74%
|
-
|
|
Jan 29
2021
|
Fred W Cooper Director |
BUY
Grant, award, or other acquisition
|
Direct |
31,153
+42.68%
|
-
|
|
Jan 29
2021
|
Alicia Syrett Director |
BUY
Grant, award, or other acquisition
|
Direct |
31,153
+26.22%
|
-
|
|
Jan 29
2021
|
Ed Brennan Director |
BUY
Grant, award, or other acquisition
|
Direct |
31,153
+2.07%
|
-
|
|
Jan 05
2021
|
Gregory A Gould Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
26,507
-6.15%
|
$53,014
$2.63 P/Share
|
|
Dec 10
2020
|
Gregory A Gould Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,564
-2.17%
|
$28,692
$3.16 P/Share
|
|
Dec 10
2020
|
Brent D Willis Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,541
-1.8%
|
$46,623
$3.16 P/Share
|
|
Dec 09
2020
|
Fred W Cooper Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,680
+50.0%
|
-
|
|
Oct 22
2020
|
Gregory A Gould Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,564
-2.13%
|
$19,128
$2.72 P/Share
|